<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MUPIROCIN - mupirocin ointment </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>MUPIROCIN OINTMENT USP, 2%<br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">Rx only <br>For Dermatologic Use</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each gram of mupirocin ointment USP, 2% contains 20 mg mupirocin in a bland water miscible ointment base (polyethylene glycol ointment, N.F.) consisting of polyethylene glycol 400 and polyethylene glycol 3350.</p>
<p>Mupirocin is a naturally occurring antibiotic. The chemical name is (<span class="Italics">E</span>)-(2<span class="Italics">S</span>,3<span class="Italics">R</span>,4<span class="Italics">R</span>,5<span class="Italics">S</span>)-5-[(2<span class="Italics">S</span>,3<span class="Italics">S</span>,4<span class="Italics">S</span>,5<span class="Italics">S</span>)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-β-methyl-2<span class="Italics">H</span>-pyran-2-crotonic acid,ester with 9-hydroxynonanoic acid.</p>
<p>The molecular formula of mupirocin is C<span class="Sub">26</span>H<span class="Sub">44</span>O<span class="Sub">9</span> and the molecular weight is 500.63. The chemical structure is: </p>
<div class="Figure">
<a name="f1"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e2ddaea4-d914-4bc7-8913-351e7bf2e2f7&amp;name=mupirocin-ointmen-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Application of <span class="Sup">14</span>C-labeled mupirocin ointment to the lower arm of normal male subjects followed by occlusion for 24 hours showed no measurable systemic absorption (&lt;1.1 nanogram mupirocin per milliliter of whole blood). Measurable radioactivity was present in the stratum corneum of these subjects 72 hours after application.</p>
<p>Following intravenous or oral administration, mupirocin is rapidly metabolized. The principal metabolite, monic acid, is eliminated by renal excretion, and demonstrates no antibacterial activity. In a study conducted in seven healthy adult male subjects, the elimination half-life after intravenous administration of mupirocin was 20 to 40 minutes for mupirocin and 30 to 80 minutes for monic acid. The pharmacokinetics of mupirocin has not been studied in individuals with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<div class="Section" data-sectionCode="49489-8">
<a name="s4"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Microbiology:</span> Mupirocin is an antibacterial agent produced by fermentation using the organism <span class="Italics">Pseudomonas fluorescens.</span> It is active against a wide range of gram-positive bacteria including methicillin-resistant <span class="Italics">Staphylococcus aureus</span> (MRSA). It is also active against certain gram-negative bacteria. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. Due to this unique mode of action, mupirocin demonstrates no <span class="Italics">in vitro</span> cross-resistance with other classes of antimicrobial agents.</p>
<p>Resistance occurs rarely. However, when mupirocin resistance does occur, it appears to result from the production of a modified isoleucyl-tRNA synthetase. High-level plasmid-mediated resistance (MIC &gt;1024 mcg/mL) has been reported in some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">S. aureus</span> and coagulase-negative staphylococci.</p>
<p>Mupirocin is bactericidal at concentrations achieved by topical administration. However, the minimum bactericidal concentration (MBC) against relevant pathogens is generally eight-fold to thirty-fold higher than the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC). In addition, mupirocin is highly protein bound (&gt;97%), and the effect of <span class="product-label-link" type="condition" conceptid="4343235" conceptname="Wound discharge">wound secretions</span> on the MICs of mupirocin has not been determined.</p>
<p>Mupirocin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Staphylococcus aureus</span> and <span class="Italics">Streptococcus pyogenes</span>, both <span class="Italics">in vitro</span> and in clinical studies. (See <span class="Bold"><a href="#s5">INDICATIONS AND USAGE</a>.</span>) The following <span class="Italics">in vitro</span> data are available, BUT THEIR CLINICAL SIGNIFICANCE IS UNKNOWN. Mupirocin is active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Staphylococcus epidermidis</span> and <span class="Italics">Staphylococcus saprophyticus.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Mupirocin ointment, 2% is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> due to: <span class="Italics">Staphylococcus aureus</span> and <span class="Italics">Streptococcus pyogenes</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s6"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s7"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Mupirocin ointment is not for ophthalmic use.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s8"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">If a reaction suggesting sensitivity or chemical irritation should occur with the use of mupirocin ointment 2%, treatment should be discontinued and appropriate alternative therapy for the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> instituted. As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. Mupirocin ointment is not formulated for use on mucosal surfaces. Intranasal use has been associated with isolated reports of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> and drying.</p>
<p>Polyethylene glycol can be absorbed from open <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> and damaged skin and is excreted by the kidneys. In common with other polyethylene glycol-based ointments, mupirocin ointment should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. A paraffin-based formulation- *Bactroban<span class="Sup">®</span> Nasal (mupirocin calcium ointment) - is available for intranasal use.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="s9"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> Use this medication only as directed by your healthcare practitioner. It is for external use only. Avoid contact with the eyes. The medication should be stopped and your healthcare practitioner contacted if irritation, severe <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurs. If <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> has not improved in 3 to 5 days, contact your healthcare practitioner.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s10"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span> The effect of the concurrent application of mupirocin ointment and other drug products has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s11"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> Long-term studies in animals to evaluate carcinogenic potential of mupirocin have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> did not indicate a potential for genotoxicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> reversion test (Ames), <span class="Italics">Escherichia coli</span> mutation assay, metaphase analysis of human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in male and female rats with mupirocin administered subcutaneously at doses up to 14 times a human topical dose (approximately 60 mg mupirocin per day) on a mg/m<span class="Sup">2</span> basis and revealed no evidence of impaired fertility and reproductive performance from mupirocin.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s12"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Teratogenic Effects.Pregnancy Category B:</span> Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 22 and 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) on a mg/m<span class="Sup">2</span> basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during opregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s13"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when <span class="Italics">mupirocin ointment</span> is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s14"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> The safety and effectiveness of <span class="Italics">mupirocin ointment</span> have been established in the age range of 2 months to 16 years. Use of <span class="Italics">mupirocin ointment</span> in these age groups is supported by evidence from adequate and well-controlled studies of <span class="Italics">mupirocin ointment</span> in <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> in pediatric patients studied as a part of the pivotal clinical trials. (See <span class="Bold"><a href="#s17">CLINICAL STUDIES</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s15"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following local adverse reactions have been reported in connection with the use of <span class="Italics">mupirocin ointment</span> : burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in 1.5% of patients; <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> in 1% of patients; <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, and increased exudate in less than 1% of patients.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s16"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">A small amount of mupirocin ointment should be applied to the affected area three times daily. The area treated may be covered with a gauze dressing if desired. Patients not showing a clinical response within 3 to 5 days should be re-evaluated.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s17"></a><a name="section-10"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">The efficacy of topical <span class="Italics">mupirocin ointment</span> in <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> was tested in two studies. In the first, patients with <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> were randomized to receive either <span class="Italics">mupirocin ointment</span> or vehicle placebo t.i.d. for 8 to 12 days. Clinical efficacy rates at end of therapy in the evaluable populations (adults and pediatric patients included) were 71% for <span class="Italics">mupirocin ointment</span> (n=49) and 35% for vehicle placebo (n=51). Pathogen eradication rates in the evaluable populations were 94% for <span class="Italics">mupirocin ointment</span> and 62% for vehicle placebo. There were no side effects reported in the group receiving <span class="Italics">mupirocin ointment.</span> In the second study, patients with <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> were randomized to receive either <span class="Italics">mupirocin ointment</span> t.i.d. or 30 to 40 mg/kg oral erythromycin ethylsuccinate per day (this was an unblinded study) for 8 days. There was a follow-up visit 1 week after treatment ended.</p>
<p>Clinical efficacy rates at the follow-up visit in the evaluable populations (adults and pediatric patients included) were 93% for <span class="Italics">mupirocin ointment</span> (n=29) and 78.5% for erythromycin (n=28). Pathogen eradication rates in the evaluable patient populations were 100% for both test groups. There were no side effects reported in the <span class="Italics">mupirocin ointment</span> group.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-10.1"></a><p></p>
<h2>Pediatrics</h2>
<p class="First">There were 91 pediatric patients aged 2 months to 15 years in the first study described above. Clinical efficacy rates at end of therapy in the evaluable populations were 78% for <span class="Italics">mupirocin ointment</span> (n=42) and 36% for vehicle placebo (n=49). In the second study described above, all patients were pediatric except two adults in the group receiving <span class="Italics">mupirocin ointment</span>. The age range of the pediatric patients was 7 months to 13 years.</p>
<p>The clinical efficacy rate for <span class="Italics">mupirocin ointment</span> (n=27) was 96%, and for erythromycin it was unchanged (78.5%).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Mupirocin Ointment USP, 2% is supplied <br>      <br>      <span class="Bold">NDC 54868-4958-0</span>       22 gram tube</p>
<p>Store at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].</p>
<p>*Bactroban<span class="Sup">®</span> Nasal is a registered trademark of 
SmithKline Pharmaceuticals.</p>
<p><span class="Bold">E. FOUGERA &amp; CO.</span><br>A division of Nycomed US 
Inc.<br>MELVILLE, NEW YORK 11747</p>
<p>I2352B<br>R9/07</p>
<br><br>Relabeling of "Additional Barcode"  by:<br>Physicians Total Care, Inc.<br>Tulsa, OK     74146<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s20"></a><a name="section-12"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 22 G </h1>
<p class="First"><span class="Bold">FOUGERA</span><span class="Sup">® </span><span class="Bold">   </span>Rx only </p>
<p><span class="Bold">MUPIROCIN OINTMENT USP, 2%</span></p>
<p>For dermatologic use only. </p>
<p>Keep out of reach of<br>children. </p>
<p><span class="Bold">NET WT 22 grams</span></p>
<p><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 22 G " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e2ddaea4-d914-4bc7-8913-351e7bf2e2f7&amp;name=package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MUPIROCIN 		
					</strong><br><span class="contentTableReg">mupirocin ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4958(NDC:0168-0352)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MUPIROCIN</strong> (MUPIROCIN) </td>
<td class="formItem">MUPIROCIN</td>
<td class="formItem">20 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4958-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">22 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065192</td>
<td class="formItem">12/05/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>eca9dbf4-887f-4b07-87ef-e9544fa84c4d</div>
<div>Set id: e2ddaea4-d914-4bc7-8913-351e7bf2e2f7</div>
<div>Version: 1</div>
<div>Effective Time: 20090402</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
